Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast

April 15, 2014
Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S
Conference|Annual Meeting of the American Radium Society (ARS)

Due to the rarity of Paget disease (PD), the role of breast conserving surgery (BCS) and radiation therapy (RT) is not fully defined. The specific aims of this analysis are to study national patterns of care in the local management of PD and to determine breast cancer–specific survival (BCSS) by type of treatment in a large population-based cohort.

Mariam P. Korah, MD, Eugene Chung, MD, PhD, JD; Department of Radiation Oncology, USC Keck School of Medicine

Purpose and Objectives: Paget disease (PD) of the breast is a condition characterized by infiltration of the epidermis of the nipple with neoplastic cells with or without an underlying malignancy of the breast parenchyma. Due to the rarity of PD, the role of breast conserving surgery (BCS) and radiation therapy (RT) is not fully defined. The specific aims of this analysis are to study national patterns of care in the local management of PD and to determine breast cancer–specific survival (BCSS) by type of treatment in a large population-based cohort.

Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried for women ≥ 20 years of age diagnosed with Tis–T2 N0 M0 mammary PD who underwent definitive surgery +/– RT from 1998–2010, with minimum follow-up of 6 months. The cohort was stratified by type of treatment into four groups: BCS, BCS + RT, mastectomy (M), or M + RT. Clinical covariates were compared between the groups using the chi-square test. Cox multivariable regression analyses were performed to determine predictors of BCSS. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test.

Results: The median follow-up time was 5 years (range: 0.5–12.9 yr). The study cohort comprised 1,509 women, most of whom were ≥ 50 years (79%). The distribution of underlying histologic subtypes was as follows: PD with infiltrating ductal carcinoma (IDC, 43%), PD with ductal carcinoma in situ (DCIS, 46%), and PD with no underlying tumor (11%). High-grade histology was identified in 48% of patients, with estrogen receptor and progesterone receptor positivity in 27% and 18% of patients, respectively. Allocation to treatment groups was as follows: BCS (n = 200), BCS + RT (n = 216), M (n = 1,046), and M + RT (n = 47). Mastectomy rates were highest among patients with PD-IDC (87%). Rates of mastectomy were 74% in the early study period (1998–2004) vs 71% in the latter study period (2005–2010) (P = .12). Overall, lymph node sampling or dissection was performed in 72% of patients: 92% of those with PD-IDC, 61% of those with PD-DCIS, and 44% of those with PD and no demonstrable tumor. BCSS at 5 and 8 years was 93% and 91% for PD-IDC, 98% and 96% for PD-DCIS, and 95% and 95% for PD without underlying tumor, respectively. BCSS was higher among patients in the BCS + RT group (94% at 8 years) compared with those who received BCS alone (91% at 8 years) (P = .54). No difference in BCSS was noted between the BCS + RT and M-alone groups (94% at 8 years) (P = .98). After adjusting for patient and tumor characteristics, no differences were observed in BCSS based on type of surgery (P = .61). Patients who required postmastectomy RT had poorer pretreatment tumor characteristics and inferior BCSS (83% at 8 years).

Conclusions: This population-based analysis shows that mastectomy with lymph node assessment is the most commonly employed approach for local disease management in early-stage PD. Rates of mastectomy have remained relatively constant throughout the study era. Despite conferring comparable rates of BCSS to mastectomy, BCS + RT appears to be underutilized in the management of PD of the breast.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content
Advertisement

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Related Content
Advertisement

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.